Long acting GLP-1 receptor agonist (injectable)
Polyethylene glycol loxenatide 0.3 mg injection once weekly
PEGLOX_SC_0p3MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.32 (0.00 to 25.99) | 0.52 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.12 (0.00 to 3.36) | 0.81 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.22 (0.16 to 13.74) | 0.43 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.14 (0.19 to 6.89) | 0.59 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.74 (1.07 to 14.43) | 0.37 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.97 (0.49 to 29.17) | 0.45 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.34 (0.22 to 9.38) | 0.55 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.69 (0.04 to 10.85) | 0.52 |